Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Press releases
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced it has received ...
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces dosing in the f ...
Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures
Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study ...
Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...
Abliva intends to start a pivotal KL1333 study second half 2021
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...
Abliva arranges Mitochondria Day on 16 September 2020 – preliminary program
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Abliva arranges Mitochondria Day on 16 September 2020
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI), today announced an increase of the number of shares and votes in the company of 26,666,666 as a result of a performed directed rights issue, resolved by the Board o ...
Abliva receives positive FDA feedback on its KL1333 development plan
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it has received positive feedback from the US Food and Drug Administration (“FDA”) on its KL1333 clinical development plan for the treatment of ...